Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A

Blood

Volumn 124, Issue 20, 2014, Pages 3165-3171

  Muto, Atsushi ^a   Yoshihashi, Kazutaka ^a   Takeda, Minako ^a   Kitazawa, Takehisa ^a   Soeda, Tetsuhiro ^a   Igawa, Tomoyuki ^a   Sampei, Zenjiro ^a   Kuramochi, Taichi ^a   Sakamoto, Akihisa ^a   Haraya, Kenta ^a   Adachi, Kenji ^a   Kawabe, Yoshiki ^a   Nogami, Keiji ^b   Shima, Midori ^b   Hattori, Kunihiro ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACE 910 ANTIBODY; BISPECIFIC ANTIBODY; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 9A; HEMOGLOBIN; HEMOSTATIC AGENT; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGENICITY; ARTICLE; AUTOPSY; CHO CELL LINE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG HALF LIFE; HEK293 CELL LINE; HEMARTHROSIS; HEMOGLOBIN BLOOD LEVEL; HEMOPHILIA A; MACACA FASCICULARIS; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIMATE MODEL; PROPHYLAXIS; ANIMAL; CELL LINE; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; HEMORRHAGE; HUMAN; IMMUNOLOGY; JOINT; MOUSE; PATHOLOGY;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL LINE; DISEASE MODELS, ANIMAL; FACTOR IXA; FACTOR X; HEMOPHILIA A; HEMORRHAGE; HUMANS; JOINTS; MACACA FASCICULARIS; MALE; MICE;

EID: 84911438456     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-07-585737     Document Type: Article

References (35)

1. Gringeri A, Muc¸a-Perja M, Mangiafico L, von Mackensen S. Pharmacotherapy of haemophilia A. Expert Opin Biol Ther. 2011;11(8):1039-1053.
2. Berntorp E, Shapiro AD. Modern haemophilia care. Lancet. 2012;379(9824):1447-1456.
3. Roosendaal G, Lafeber FP. Blood-induced joint damage in hemophilia. Semin Thromb Hemost. 2003;29(1):37-42.
4. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535-544.
5. Oldenburg J. Prophylaxis in bleeding disorders. Thromb Res. 2011;127(suppl 1):S14-S17.
6. Ragni MV, Fogarty PJ, Josephson NC, Neff AT, Raffini LJ, Kessler CM. Survey of current prophylaxis practices and bleeding characteristics of children with severe haemophilia A in US haemophilia treatment centres. Haemophilia. 2012;18(1):63-68.
7. Astermark J, Donfield SM, DiMichele DM, et al; FENOC Study Group. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood. 2007;109(2):546-551.
8. Jimenez-Yuste V, Rodriguez-Merchan EC, Alvarez MT, Quintana M, Martin-Salces M, Hernandez-Navarro F. Experiences in the prevention of arthropathy in haemophila patients with inhibitors. Haemophilia. 2008;14(suppl 6):28-35.
9. Hay CR, DiMichele DM; International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood. 2012;119(6):1335-1344.
10. Valentino LA, Ismael Y, Grygotis M. Novel drugs to treat hemophilia. Expert Opin Emerg Drugs. 2010;15(4):597-613.
11. Lillicrap D. The future of hemostasis management. Pediatr Blood Cancer. 2013;60(suppl 1):S44-S47.
12. Pipe SW. The hope and reality of long-acting hemophilia products. Am J Hematol. 2012;87(suppl 1):S33-S39.
13. Kaufman RJ, Powell JS. Molecular approaches for improved clotting factors for hemophilia. Blood. 2013;122(22):3568-3574.
14. Kitazawa T, Igawa T, Sampei Z, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med. 2012;18(10):1570-1574.
15. Sampei Z, Igawa T, Soeda T, et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS ONE. 2013;8(2):e57479.
16. Muto A, Yoshihashi K, Takeda M, et al. Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation. J Thromb Haemost. 2014;12(2):206-213.
17. Collins PW. Personalized prophylaxis. Haemophilia. 2012;18(suppl 4):131-135.
18. Den Uijl IE, Mauser Bunschoten EP, Roosendaal G, et al. Clinical severity of haemophilia A: does the classification of the 1950s still stand? Haemophilia. 2011;17(6):849-853.
19. Ponce R, Abad L, Amaravadi L, et al. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies. Regul Toxicol Pharmacol. 2009;54(2):164-182.
20. Deng R, Iyer S, Theil FP, Mortensen DL, Fielder PJ, Prabhu S. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned? MAbs. 2011;3(1):61-66.
21. Franchini M, Targher G, Montagnana M, Lippi G. Laboratory, clinical and therapeutic aspects of acquired hemophilia A. Clin Chim Acta. 2008;395(1-2):14-18.
22. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al; Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1-e47.
23. Dong JQ, Salinger DH, Endres CJ, et al. Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction. Clin Pharmacokinet. 2011;50(2):131-142.
24. Roosendaal G, Vianen ME, Wenting MJ, et al. Iron deposits and catabolic properties of synovial tissue from patients with haemophilia. J Bone Joint Surg Br. 1998;80(3):540-545.
25. Roosendaal G, van Rinsum AC, Vianen ME, van den Berg HM, Lafeber FP, Bijlsma JW. Haemophilic arthropathy resembles degenerative rather than inflammatory joint disease. Histopathology. 1999;34(2):144-153.
26. Valentino LA, Hakobyan N, Kazarian T, Jabbar KJ, Jabbar AA. Experimental haemophilic synovitis: rationale and development of a murine model of human factor VIII deficiency. Haemophilia. 2004;10(3):280-287.
27. Monahan PE. The expanding menagerie: animal models of hemophilia A. J Thromb Haemost. 2010;8(11):2469-2471.
28. Nichols TC, Dillow AM, Franck HW, et al. Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency. ILAR J. 2009;50(2):144-167.
29. Hoffman M. Animal models of bleeding and tissue repair. Haemophilia. 2008;14(suppl 3):62-67.
30. Nichols TC, Raymer RA, Franck HW, et al. Prevention of spontaneous bleeding in dogs with haemophilia A and haemophilia B. Haemophilia. 2010;16(suppl 3):19-23.
31. Porada CD, Sanada C, Long CR, et al. Clinical and molecular characterization of a re-established line of sheep exhibiting hemophilia A. J Thromb Haemost. 2010;8(2):276-285.
32. Booth CJ, Brooks MB, Rockwell S, et al. WAG-F8 (m1Ycb) rats harboring a factor VIII gene mutation provide a new animal model for hemophilia A. J Thromb Haemost. 2010;8(11):2472-2477.
33. Lozier JN, Nichols TC. Animal models of hemophilia and related bleeding disorders. Semin Hematol. 2013;50(2):175-184.
34. Kashiwakura Y, Mimuro J, Onishi A, et al. Porcine model of hemophilia A. PLoS ONE. 2012;7(11):e49450.
35. Berntorp E. Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens. Haemophilia. 2009;15(6):1219-1227.